Skip to main content
SpringerLink
Log in

Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial

  • Research Letter
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nidorf SM, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372.

    Article  CAS  PubMed  Google Scholar 

  2. Tardif JC, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388.

    Article  CAS  PubMed  Google Scholar 

  3. Hansten PD, et al. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf. 2022. https://doi.org/10.1007/s40264-022-01265-1.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNa guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625.

    Article  PubMed  Google Scholar 

  5. van Broekhoven A, et al. The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatine kinase levels: safety insights from the low-dose colchicine 2 (LoDoCo2) trial. Clin Drug Investig. 2022;42(11):977–85. https://doi.org/10.1007/s40261-022-01209-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brewster LM, et al. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J. 2007;154(4):655–61. https://doi.org/10.1016/j.ahj.2007.06.008.

    Article  CAS  PubMed  Google Scholar 

  7. Janssen L, et al. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019.

    Article  PubMed  Google Scholar 

  8. Kyriakides T, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010;17(6):767–73. https://doi.org/10.1111/j.1468-1331.2010.03012.x.

    Article  CAS  PubMed  Google Scholar 

  9. Collaboration CTT. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–45. https://doi.org/10.1016/S0140-6736(22)01545-8.

    Article  Google Scholar 

  10. Fiolet ATL, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–75. https://doi.org/10.1093/eurheartj/ehab115.

    Article  CAS  PubMed  Google Scholar 

  11. Robinson PC, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. https://doi.org/10.1016/j.amjmed.2021.07.025.

    Article  CAS  PubMed  Google Scholar 

  12. Gomez-Lumbreras A, et al. Drugs that interact with colchicine via inhibition of cytochrome P450 3A4 and P-glycoprotein: a signal detection analysis using a database of spontaneously reported adverse events (FAERS). Ann Pharmacother. 2023. https://doi.org/10.1177/10600280221148031.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands

    Amber van Broekhoven & Jan H. Cornel

  2. Department of Medicine, McMaster University, Hamilton, ON, Canada

    John W. Eikelboom

  3. Heart and Vascular Research Institute of Western Australia, Perth, Australia

    Stefan M. Nidorf

  4. GenesisCare Western Australia, Perth, Australia

    Stefan M. Nidorf

  5. Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands

    Arend Mosterd & Jan H. Cornel

  6. Department of Cardiology, Meander Medical Centre, Amersfoort, The Netherlands

    Arend Mosterd

  7. Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands

    Jan H. Cornel

Authors
  1. Amber van Broekhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Eikelboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan M. Nidorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arend Mosterd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan H. Cornel
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the LoDoCo2 investigators

Corresponding author

Correspondence to Jan H. Cornel.

Ethics declarations

Funding

This work was supported by the National Health Medical Research Council of Australia, a grant from the Sir Charles Gairdner Research Advisory Committee, the Withering Foundation the Netherlands, the Netherlands Heart Foundation, the Netherlands Organization for Health Research and Development, and a consortium of Teva, Disphar, and Tiofarma in the Netherlands.

Conflicts of Interest

AvB and SMN have nothing to disclose. JWE reports consulting/honoraria support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis, Servier and grants and/or in-kind support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis. JHC reports membership of advisory boards with Amgen, AstraZeneca.

Availability of Data and Material

The data underlying this article will be shared on reasonable request to the Steering Committee via A.Mosterd@meandermc.nl.

Ethics Approval

The trial protocol was approved by a central institutional review board in each participating country. Trial registration: https://www.anzctr.org.au ACTRN12614000093684, 24 January 2014.

Consent to Participate

All participants gave their informed consent to have blood drawn at the close-out visit at the end of the LoDoCo2 trial.

Consent for Publication

Not applicable.

Code Availability

Not applicable.

Author Contributions

All authors contributed to the conception of the strategy. The first draft of the manuscript was written by AvB and SMN and all authors critically reviewed and approved the final manuscript.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 275 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Broekhoven, A., Eikelboom, J.W., Nidorf, S.M. et al. Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial. Clin Drug Investig 43, 575–577 (2023). https://doi.org/10.1007/s40261-023-01287-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-023-01287-2

Search

Navigation